CSL Limited (ASX:CSL)

Australia · Delayed Price · Currency is AUD

194.23

-3.76 (-1.90%)

Sep 26, 2025, 4:13 PM AEST

CSL Limited Employees

CSL Limited had 29,904 employees as of June 30, 2025. The number of employees decreased by 2,794 or -8.54% compared to the previous year.

Employees

29,904

Change (1Y)

-2,794

Growth (1Y)

-8.54%

Revenue / Employee

793.56K AUD

Profits / Employee

153.12K AUD

Market Cap

93.96B

Employees Chart

Employees History

Date	Employees	Change	Growth
Jun 30, 2025	29,904	-2,794	-8.54%
Jun 30, 2024	32,698	633	1.97%
Jun 30, 2023	32,065	2,065	6.88%
Jun 30, 2022	30,000	5,000	20.00%
Jun 30, 2021	25,000	-2,000	-7.41%
Jun 30, 2020	Pro	Pro	Pro
Jun 30, 2019	Pro	Pro	Pro
Jun 30, 2016	Pro	Pro	Pro
Jun 30, 2015	Pro	Pro	Pro

Related Stocks

Company Name	Employees
Pro Medicus	132
Cochlear	5,500
Sonic Healthcare	45,000
Ramsay Health Care	90,000
Telix Pharmaceuticals	234
Ansell	15,000
Mesoblast	81
Neuren Pharmaceuticals	8

Employee Rankings

CSL Limited News

5 weeks ago - CSL Limited falls as layoffs overshadow FY25 results - Seeking Alpha
5 weeks ago - CSL Limited (CSLLY) Q4 2025 Earnings Call Transcript - Seeking Alpha
5 weeks ago - Full Year 2025 CSL Ltd Earnings Presentation Transcript - GuruFocus
5 weeks ago - CSL Limited 2025 Q4 - Results - Earnings Call Presentation - Seeking Alpha
5 weeks ago - Australian biopharma firm CSL posts 14% rise in annual profit - Reuters
3 months ago - U.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All Patients From the Start - PRNewsWire
4 months ago - England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy - PRNewsWire
5 months ago - CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy - PRNewsWire